Physician profile
Andrew C Kramer
NPI 1184607681
$107,571.19
in general payments reported to CMS, 2019-2025
46 companies · $12K in 2025
The $12K reported for 2025 was more than what 95% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32K · 2020: $36K · 2021: $2,835 · 2022: $493 · 2023: $22K · 2024: $2,597 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $21K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,640 · Food and Beverage: $3,828 · Travel and Lodging: $2,692.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $21,175.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,640.00 |
| Food and Beverage | $3,828.30 |
| Travel and Lodging | $2,691.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $47,558.88 | 2019-2025 | General - Erectile Dysfunction, Ams 700, Ams 700 Cxr Rte Kit |
| Rigicon,INC. | $43,081.48 | 2020-2023 | Rigi10 Malleable Penile Prosthesis |
| Coloplast Corp | $11,435.28 | 2019-2025 | |
| Baxter Healthcare | $1,262.57 | 2019 | |
| Teleflex LLC | $1,041.08 | 2021-2025 | Urolift |
| Abbvie INC. | $417.21 | 2021-2025 | |
| Janssen Biotech, INC. | $252.00 | 2019-2025 | Erleada, Akeega |
| Sumitomo Pharma America, INC. | $247.97 | 2023-2025 | Gemtesa, Orgovyx |
| Tolmar, INC. | $226.98 | 2023-2025 | Eligard, Jatenzo |
| 180 Medical, INC. | $205.52 | 2021-2025 | Gentlecath, Cure Catheter, Gentlecath Glide |
| Ferring Pharmaceuticals INC. | $161.56 | 2019-2025 | Adstiladrin |
| Urogen Pharma, INC. | $144.32 | 2021 | |
| Olympus America INC. | $128.70 | 2019-2024 | Itind System |
| Progenics Pharmaceuticals, INC. | $121.84 | 2021-2022 | |
| Antares Pharma, INC. | $118.49 | 2019-2024 | Xyosted |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Kramer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.